Relationship between serum visfatin and serum adiponectin level and the pathology of nonalcoholic fatty liver disease

Zhu ChaoHui; Chen DongFeng; Ai ZhengLin; Yang Li; Min Min

Issue 7

Jul. 2011

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2011 > 27(7): 735-737+748

PDF( 884 KB)

Relationship between serum visfatin and serum adiponectin level and the pathology of nonalcoholic fatty liver disease

Published Date: 2011-07-20

Abstract

Abstract

Objective To explore the relationship between serum visfatin and adiponectin levels and the pathology of NAFLD.Methods 54 patients were divided into 3 groups according to the pathology, including control group, simple steatosis group, and nonalcoholic steatohepatitis group.Serum visfatin and adiponectin levels were measured by enzymelinked immunosorbent assay.Results Among the 54 patients, control group includes 23 cases;simple steatosis group comprises of 11 cases;while nonalcoholic steatohepatitis group contains 20 cases.The level of serum visfatin of NASH group is lower than that of control group and simple steatosis group.Moreover, the change of serum adiponectin of NASH is as same as serum visfatin.Conclusion In NAFLD patients, the more severe the changes of steatosis and inflammation of the histopathology in liver, the lower levels of visfatin and adiponectin in plasma concentrations were showed.
- fatty liver,
- visfatin

FullText(HTML)

References(11)

References

[1]Musso G, Gambino R, Cassader M.Non-alcoholic fatty liverdisease from pathogenesis to management:an update[J].Obes Rev, 2010, 11 (6) :430-445.

[2]Kamada Y, Takehara T, Hayashi N.Adipocytokines and liverdisease[J].J Gastroenterol, 2008, 43 (11) :811-822.

[3]Low S, Chin MC, Ma S, et al.Rationale for redefining obesityin Asians[J].Ann Acad Med Singapore, 2009, 38 (1) :66-69.

[4]中华医学会.非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志, 2006, 14 (3) :161-163.

[5]沙卫红, 李瑜元.2009年美国消化疾病会议周概况[J].中华消化杂志, 2009, 29 (8) :547-549.

[6]Fierbinteanu-Braticevici C, Dina I, Petrisor A, et al.Noninvasiveinvestigations for non alcoholic fatty liver disease and liverfibrosis[J].World J Gastroenterol, 2010, 16 (38) :4784-4791.

[7]Lewis JR, Mohanty SR.Nonalcoholic fatty liver disease:areview and update[J].Dig Dis Sci, 2010, 55 (3) :560-578.

[8]Balsano C, Alisi A, Nobili V.Liver fibrosis and therapeuticstrategies:the goal for improving metabolism[J].Curr DrugTargets, 2009, 10 (6) :505-512.

[9]Lonardo A, Carani C, Carulli N, et al.'Endocrine NAFLD'ahormonocentric perspective of nonalcoholic fatty liver diseasepathogenesis[J].J Hepatol, 2006, 44 (6) :1196-1207.

[10]Fukuhara A, Matsuda M, Nishizawa M, et al.Visfatin:a proteinsecreted by visceral fat that mimics the effects of insulin[J].Science, 2005, 307 (5708) :426-430.

[11]Targher G, Bertolini L, Rodella S, et al.Associations betweenplasma adiponectin concentrations and liver histologyin patients with nonalcoholic fatty liver disease[J].ClinEndocrinol (Oxf) , 2006, 64 (6) :679-683.

Relative Articles

[1]	Wang CuiHua, Yue Yan. Research progress in relationship of leptin and adiponectin with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(8): 1351-1354. doi: 10.3969/j.issn.1001-5256.2015.08.045
[2]	Cui RuiBing, Yan Ming. Application of lipid- regulating drugs in non- alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1038-1041. doi: 10.3969/j.issn.1001-5256.2015.07.010
[3]	Zhang Yu, Cheng Jun. Hepatitis C virus related fatty liver[J]. Journal of Clinical Hepatology, 2015, 31(7): 1034-1037. doi: 10.3969/j.issn.1001-5256.2015.07.009
[4]	Niu TongHong, Zhang Mei, Jiang Man, Xin YongNing, Xuan ShiYing. Research advances in gene polymorphisms in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 947-951. doi: 10.3969/j.issn.1001-5256.2013.12.020
[5]	Li GuangMing, Fan JianGao. Research progress in role of iron overload in non- alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 897-900. doi: 10.3969/j.issn.1001-5256.2013.12.006
[6]	Wang Zi, Hu DaoYu. Research advances in quantitative evaluation of liver fat in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 894-896. doi: 10.3969/j.issn.1001-5256.2013.12.005
[7]	Zhou XiaoLi, He LanJie. Relationship between nonalcoholic fatty liver disease and adipocyte fatty acid- binding protein[J]. Journal of Clinical Hepatology, 2013, 29(12): 914-918. doi: 10.3969/j.issn.1001-5256.2013.12.010
[8]	Shi JunPing, Xun YunHao. Progress in treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 890-893. doi: 10.3969/j.issn.1001-5256.2013.12.004
[9]	Dong Shu, Liu Ping, Sun MingYu. Role of “two-hit” in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(7): 551-555.
[10]	Hu Na, Cheng Hao, Shi JunPing. Introduction to the AASLD/ACG/AGA practice guideline: Diagnosis and management of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(7): 487-492.
[11]	Zhang LiLi, Xiang XiaoXing. Role of Kupffer cell in pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(8): 873-876.
[12]	Li Juan, Zhang LingYi. Vascular endothelial growth factor and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(8): 869-872.
[13]	Jing XiaoZhen, Liu Jing, Qian Hai. The therapeutic efficacy of magnesium isoglycyrrhizinate on rats with non alcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2011, 27(3): 295-297.
[14]	Kong Yin, Zhang LingYi. The role of leptin and adiponectin in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(4): 441-443.
[15]	Cha Ying, Liu Jun, Sheng Li, Chen ZaoPing, Yang LingDi, Chen QinDa, Liao XiaoHuan, Meng LingPing. Relationship between adiponectin and β-cell function and insulin resistance in female patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(4): 420-423.
[16]	Zhou ShuYun, Sun ZheYing. Therapeutic efficacy of polyunsaturated phosphatidylcholine on fatty liver disease[J]. Journal of Clinical Hepatology, 2010, 26(3): 286-287.
[17]	Xiang GuoQing, Meng XiaoDan, Wang BingYuan. Prevalence of fatty liver among people with different occupation in Shenyang[J]. Journal of Clinical Hepatology, 2010, 26(3): 283-285.
[18]	Xu YuWu, Liu YingZi, Fan JianGao, Yang Lin. Preliminary study on quantification of ultrasonographic classification of fatty liver [J]. Journal of Clinical Hepatology, 2010, 26(3): 267-268+280.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2785) PDF downloads(984)

Relationship between serum visfatin and serum adiponectin level and the pathology of nonalcoholic fatty liver disease

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Relationship between serum visfatin and serum adiponectin level and the pathology of nonalcoholic fatty liver disease

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content